Catherine is Chief Executive Officer at Chroma Medicine and an Advisor at Atlas Venture. She also serves as an Independent Board member at Generation Bio, Tenaya Therapeutics and Dyne Therapeutics, Inc. Previously, she was Chief Research and Development Officer at Obsidian Therapeutics where she led research and discovery efforts for their engineered cell and gene therapies. Prior to Obsidian Therapeutics, Catherine was an Entrepreneur in Residence at Atlas Venture and Chief Medical Officer at Sarepta Therapeutics. In addition, Catherine held various leadership roles at Regeneron and Amgen. Catherine received her MD from the University of Chicago and trained as a nephrologist and earned her MS in epidemiology at University of Washington.